Evidence suggests 20-CT scans and MRI.

There are more than 1.5 million CRC survivors in the U.S.

The CRC remains the second leading cause of cancer death.

Current Clinicopathologic tools are limited in their ability to correctly identify patients at high risk of recurrence.

Innovative Guardant Reveal technology enables groundbreaking performance, speed, and ease of use.

Circulating tumor DNA (ctDNA) outperforms standard-of-care CEA and all currently used clinicopathologic features at predicting risk for patients at high risk of recurrence.

- Most patients with ctDNA detected after surgery will eventually recur.
- ctDNA predicts more high-risk patients than CEA and all current clinicopathological features.
- Evidence suggests 20-30% of ctDNA+ patients may be treated effectively with adjuvant chemotherapy to prevent recurrence and have good outcomes.
- The Guardant Reveal test shows 91% sensitivity for correctly detecting ctDNA at different surveillance timepoints.

Innovative Guardant Reveal technology enables groundbreaking performance, speed, and ease of use.

- Interrogates two signals, genomic alterations and methylation, to achieve high sensitivity.
- Distinguishes between cancerous tumor and non-tumor signals without the need for tissue biopsy.
Provides results in only 7 days for faster time to treatment and easier surveillance
Can be initiated at any time, as soon as 4 weeks after surgery
- Guardant Reveal improves the management of early-stage CRC for oncologists across multiple timepoints:

The first indication for Guardant Reveal is early-stage CRC with additional cancer types to follow.

**Transforming cancer care across the continuum through liquid biopsy**

Guardant Health’s vision is to transform cancer care across all stages of the disease through the power of blood. This includes for advanced cancer patients, early-stage patients, and asymptomatic people.

The company started in 2014 with the Guardant360® test for advanced cancer patients. It was the first-in-kind liquid biopsy to comprehensively sequence a patient’s cancer to reveal actionable mutations for precision medicine treatment decisions. The blood test overcame challenges of tissue biopsy to enable faster, easier, more complete genomic testing, and in 2020 the Guardant360® CDx test became the first FDA-approved comprehensive liquid biopsy. Advanced cancer and the company’s work with its Guardant360 test has laid the foundation, with each blood sample sequenced fueling progress toward earlier cancer management.

In 2021, the introduction of the Guardant Reveal™ test for residual disease and recurrence monitoring of early-stage cancer marks the next important step along the cancer care continuum. The innovative test holds the promise to transform management of early-stage cancer for millions of patients and survivors. Studies are currently underway to validate the clinical utility in practice of the Guardant Reveal test (COBRA Escalation Trial, ACT–III Escalation Trial, and PEGASUS De-Escalation Trial) as well as the LUNAR-2 test for early-stage CRC detection and screening (ECLIPSE Trial).

**References:**

3. American Cancer Society: Colorectal Cancer Facts & Figures 2020